Showing results (121-130 of 391) with videos related to

Sort By:
Pageof 40
Rheumatology International|July 2, 2013
Sex differences in patients with systemic lupus erythematosus from Northwest SpainMaria D Alonso, Francisco Martínez-Vázquez, Leyre Riancho-Zarrabeitia, et al.
The Journal of Rheumatology|May 17, 2012
Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritisF David Carmona, Aurora Serrano, Luis Rodríguez-Rodríguez, et al.
European Journal of Internal Medicine|April 22, 2026
Cocaine-induced ANCA-associated vasculitis: Cohort analysis from a referral center and literature reviewNuria Garvín Grande, María Pilar Ortiz-Lavín, Vanesa Calvo-Río, et al.
The Journal of Dermatology|June 6, 2022
Biomarkers of endothelial dysfunction and atherosclerosis in hidradenitis suppurativaMarcos A González-López, J Gonzalo Ocejo-Viñals, Ana E López-Sundh, et al.
Seminars in Arthritis and Rheumatism|October 3, 2017
<sup>18</sup>F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patientsIsabel Martínez-Rodríguez, Mikel Jiménez-Alonso, Remedios Quirce, et al.
The Lancet. Rheumatology|January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialRoy Fleischmann, Alan Friedman, Edit Drescher, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid ArthritisIván Ferraz-Amaro, Alfonso Corrales, Belén Atienza-Mateo, et al.
RMD Open|April 14, 2017
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritisPaul Emery, Ricardo Blanco, Jose Maldonado Cocco, et al.
Clinical and Experimental Rheumatology|May 29, 2013
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapyJosé A Miranda-Filloy, Raquel López-Mejias, Fernanda Genre, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Pageof 40